Mkts

Xeris Biopharma Holdings, Inc.

NASDAQ: XERS
$15.82+0.62 (+4.08%)
As of Nov 9, 3:32 PM ET

Key statistics

Day range
15.0915.94
52-week range
5.2515.21
Today
Open15.33
Previous close15.82
Volume—
Valuation
Market cap2.78B
P/E ratio—
EPS (TTM)-0.11
Income & risk
Dividend / yield—
Beta0.63
Avg volume2.41M
Discussion

XERS News

Stories mentioning XERS from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue83,12785,80774,38071,53960,11960,09954,26848,065
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development8,7837,8747,4838,0557,7536,0925,8885,759
Sales General & Admin53,14447,50246,45944,39344,01840,13944,96939,993
Total Operating Expenses
Operating Income (Loss)7,91616,7736,7314,482(3,090)1,679(12,893)(8,187)
Interest Income
Interest Expense
Other Expense(5,682)(5,692)(6,110)(6,410)(6,130)(6,792)(6,169)(6,069)
Pretax Income
Tax Provision0.000.000.000.000.000.00(3,324)749.00
Net Income (Loss)2,23411,081621.00(1,928)(9,220)(5,113)(15,738)(15,005)
Earnings Per Share (Basic)0.010.070.00(0.01)(0.06)(0.03)(0.11)(0.10)
Earnings Per Share (Diluted)0.010.060.00(0.01)(0.06)(0.03)(0.11)(0.10)
Weighted Average Shares Outstanding (Basic)170,523160,425163,650159,459152,446146,773148,994148,346
Weighted Average Shares Outstanding (Diluted)177,631172,743177,617159,459152,446146,773148,994148,346

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About XERS

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is a stock listed on the Nasdaq Stock Market under the ticker symbol XERS. It last traded at $15.82 (Nov 9, 2026, 3:32 PM ET), up 4.1% on the day. That gives Xeris Biopharma a market capitalisation of $2.8B.

Over the past 52 weeks XERS has traded between $5.25 and $15.21.

Revenue for the quarter ended Mar 31, 2026 was $83.1M; net income $2.2M. Revenue was up 38.3% from $60.1M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$83.1M$2.2M2.7%
Dec 31, 2025$85.8M$11.1M12.9%
Sep 30, 2025$74.4M$621.0K0.8%
Jun 30, 2025$71.5M-$1.9M-2.7%

From Xeris Biopharma’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…